✦ LIBER ✦

Platelet-derived growth factor receptor independent proliferation of human glioblastoma cells: selective tyrosine kinase inhibitors lack antiproliferative activity

✍ Scribed by Dietmar Gross; Günther Bernhardt; Armin Buschauer

Publisher: Springer-Verlag
Year: 2006
Tongue: English
Weight: 594 KB
Volume: 132
Category: Article
ISSN: 1432-1335
DOI: 10.1007/s00432-006-0109-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Peroxisome proliferator-activated recept

Peroxisome proliferator-activated receptor γ transcriptional regulation is involved in platelet-derived growth factor–induced proliferation of human hepatic stellate cells

✍ Andrea Galli; David Crabb; Donna Price; Elisabetta Ceni; Renata Salzano; Caloger 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 405 KB 👁 1 views

Abbreviations: HSC, hepatic stellate cells; ␣-SMA, ␣ smooth muscle actin; PDGF, platelet-derived growth factor; PPAR␥, peroxisome proliferator-activated receptor ␥; 9-cisRA, 9-cis retinoic acid; RXR, retinoic X receptor; 15d-PGJ 2 , 15-deoxy-⌬ 12,14 prostaglandin J 2 ; [ 3 H]TdR, [methyl-3 H]thymidi

A potent protein-tyrosine kinase inhibit

A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo

✍ Nicholas B. Lydon; Helmut Mett; Marcel Mueller; Michael Becker; Robert M. Cozens 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 243 KB 👁 2 views

Inhibition of proliferation and inductio

Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (‘Iressa’) is independent of EGFR expression level

✍ Manuela Campiglio; Alberta Locatelli; Clelia Olgiati; Nicola Normanno; Giulia So 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 297 KB 👁 2 views

High expression of the epidermal growth factor receptor (EGFR) in breast carcinoma confers a growth advantage to the tumor cells. The EGFR tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') has clinical activity in a wide range of tumor types, although the mechanism(s) by which it exerts its ant

A potent protein-tyrosine kinase inhibit

A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo. Int. J. Cancer,76, 154–163 (1998)

✍ N. Lydon; H. Mett; M. Mueller; M. Becker; R.M. Cozens; D. Daniels; P. Traxler; E 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 8 KB 👁 2 views

Different inhibitory effect of imatinib

Different inhibitory effect of imatinib on phosphorylation of mitogen-activated protein kinase and Akt and on proliferation in cells expressing different types of mutant platelet-derived growth factor receptor-α

✍ Akiko Ohashi; Kazuo Kinoshita; Koji Isozaki; Toshirou Nishida; Yasuhisa Shinomur 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 195 KB 👁 1 views

## Abstract Most gastrointestinal stromal tumors (GISTs) have gain‐of‐function mutations of the c‐__kit__ gene. Previously, we found 2 types of gain‐of‐function mutation of the __PDGFRA__ gene, Val^561^ to Asp and Asp^842^ to Val, in about half of GISTs without c‐__kit__ gene mutations. Although th

Antitumor activity of the selective epid

Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa® (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo

✍ Ichiro Naruse; Tohru Ohmori; Yoko Ao; Hisao Fukumoto; Toshio Kuroki; Masatomo Mo 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 216 KB 👁 1 views

## Abstract Selective tyrosine kinase inhibitors are regarded as promising antitumor agents for cancer treatment. Iressa® (ZD1839) is an orally active, selective EGFR‐TKI (epidermal growth factor receptor‐tyrosine kinase inhibitor) that blocks signal transduction pathways implicated in cancer cell